Identifying New Zealand Public Preferences for Pharmacist Prescribers in Primary Care: A Discrete Choice Experiment

Raghunandan, Rakhee; Howard, Kirsten; Marra, Carlo; Tordoff, June; Smith, Alesha

doi:10.1007/s40271-021-00529-9

Cited by 3 publications

(4 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are consistent with international DCE patient enhanced care pharmacy studies where patients express a preference for a shorter waiting time [ 15 , 16 , 18 , 25 , 26 , 28 , 33 , 34 , 36 ], a similar model of pharmacy intervention [ 15 , 17 , 19 , 20 , 24 , 28 , 31 , 35 , 36 ], and the chance of best treatment [ 18 , 28 , 29 ]. There are still very few DCE studies published on pharmacy-led integrated or collaborative care with physicians, but these also confirm preferences for integration with physicians [ 27 , 28 ].…”

Section: Discussionsupporting

confidence: 88%

“…Our results are consistent with international DCE patient enhanced care pharmacy studies where patients express a preference for a shorter waiting time [15,16,18,25,26,28,33,34,36], a…”

Section: Summary Of Key Findingssupporting

confidence: 89%

“…similar model of pharmacy intervention [15,17,19,20,24,28,31,35,36], and the chance of best treatment [18,28,29]. There are still very few DCE studies published on pharmacy-led integrated or collaborative care with physicians, but these also confirm preferences for integration with physicians [27,28].…”

Section: Plos Onementioning

confidence: 99%

“…Since then, 12 more DCE studies were published on patient preferences for a pharmacydelivered patient care service: 2 on minor ailments [25,26], 4 on medication therapy management or disease management [27][28][29][30], 2 on innovative pharmacy services [31,32], 1 on the Hepatitis C test [33], 1 on specialty medicines [34], 1 on screening for cardiovascular disease [35], and 1 on prescribing by pharmacists [36]. In 2016, Tinelli incorporated a DCE into an economic evaluation using CBA.…”

Section: Competing Interestsmentioning

confidence: 99%

See 3 more Smart Citations

Patient preferences and cost-benefit of hypertension and hyperlipidemia collaborative management model between pharmacies and primary care in Portugal: A discrete choice experiment alongside a trial (USFarmácia®)

Costa,

Guerreiro,

Teixeira

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Background Little is known about patient preferences and the value of pharmacy-collaborative disease management with primary care using technology-driven interprofessional communication under real-world conditions. Discrete Choice Experiments (DCEs) are useful for quantifying preferences for non-market services. Objectives 1) To explore variation in patient preferences and estimate willingness-to-accept annual cost to the National Health Service (NHS) for attributes of a collaborative intervention trial between pharmacies and primary care using a trial exit DCE interview; 2) to incorporate a DCE into an economic evaluation using cost-benefit analysis (CBA). Methods We performed a DCE telephone interview with a sample of hypertension and hyperlipidemia trial patients 12 months after trial onset. We used five attributes (levels): waiting time to get urgent/not urgent medical appointment (7 days/45 days; 48 hrs./30 days; same day/15 days), model of pharmacy intervention (5-min. counter basic check; 15-min. office every 3 months for BP and medication review of selected medicines; 30-min. office every 6 months for comprehensive measurements and medication review of all medicines), integration with primary care (weak; partial; full), chance of having a stroke in 5 years (same; slightly lower; much lower), and annual cost to the NHS (0€; 30€; 51€; 76€). We used an experimental orthogonal fractional factorial design. Data were analyzed using conditional logit. We subtracted the estimated annual incremental trial costs from the mean WTA (Net Benefit) for CBA. Results A total of 122 patients completed the survey. Waiting time to get medical appointment—on the same day (urgent) and within 15 days (non-urgent)—was the most important attribute, followed by 30-minute pharmacy intervention in private office every 6 months for point-of-care measurements and medication review of all medicines, and full integration with primary care. The cost attribute was not significant. Intervention patients were willing to accept the NHS annual cost of €877 for their preferred scenario. The annual net benefit per patient is €788.20 and represents the monetary value of patients’ welfare surplus for this model. Conclusions This study is the first conducted in Portugal alongside a pharmacy collaborative trial, incorporating DCE into CBA. The findings can be used to guide the design of pharmacy collaborative interventions with primary care with the potential for reimbursement for uncontrolled or at-risk chronic disease patients informed by patient preferences. Future DCE studies conducted in community pharmacy may provide additional contributions. Trial registration Current Controlled Trials (ISRCTN): ISRCTN13410498, retrospectively registered on 12 December 2018.

show abstract

Section: Discussionsupporting

confidence: 88%

“…Our results are consistent with international DCE patient enhanced care pharmacy studies where patients express a preference for a shorter waiting time [15,16,18,25,26,28,33,34,36], a…”

Section: Summary Of Key Findingssupporting

confidence: 89%

Section: Plos Onementioning

confidence: 99%

Section: Competing Interestsmentioning

confidence: 99%

See 2 more Smart Citations

Patient preferences and cost-benefit of hypertension and hyperlipidemia collaborative management model between pharmacies and primary care in Portugal: A discrete choice experiment alongside a trial (USFarmácia®)

Costa,

Guerreiro,

Teixeira

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

show abstract

Patient Preferences for Pharmacy Services: A Systematic Review of Studies Based on Discrete Choice Experiments

Riboulet,

Clairet,

Bennani

et al. 2023

Patient

View full text Add to dashboard Cite

“Prescribing for the whole person”: A qualitative study exploring prescribing pharmacist views on type 2 diabetes management in New Zealand

Norman,

Cassim,

Papa

et al. 2023

BMC Health Serv Res

View full text Add to dashboard Cite

Background Pharmacist prescribers have comprehensive pharmacotherapy knowledge that can be useful for management of complex health conditions such as type 2 diabetes, yet the number of pharmacist prescribers working in New Zealand primary care is low. Aim To explore the experiences of pharmacist prescribers in supporting type 2 diabetes management in New Zealand primary care. Methods Qualitative research design using semi-structured interviews with six pharmacist prescribers working in NZ primary care. Thematic analysis guided this study and themes were finalised with the wider research team. Results Three major themes were identified: team approach, health inequity and the role of a pharmacist prescriber. This study found that pharmacist prescribers may improve health equity by providing advanced pharmacotherapy knowledge within a wider primary care team to support complex patient needs and understanding the wider social determinants of health that impact effective diabetes management. Participants reportedly had more time to spend with patients (than GPs or nurses) and could also contribute to improving health outcomes by directly educating and empowering patients. Conclusion The views of pharmacist prescribers have seldom been explored and this study suggests that their role may be under-utilised in primary care. In particular, pharmacist prescribers can provide specialist prescribing (and often mobile) care, and may contribute to improving health outcomes and reducing inequity when used as part of a multi-disciplinary team.

show abstract

Identifying New Zealand Public Preferences for Pharmacist Prescribers in Primary Care: A Discrete Choice Experiment

Cited by 3 publications

References 46 publications

Patient preferences and cost-benefit of hypertension and hyperlipidemia collaborative management model between pharmacies and primary care in Portugal: A discrete choice experiment alongside a trial (USFarmácia®)

Patient preferences and cost-benefit of hypertension and hyperlipidemia collaborative management model between pharmacies and primary care in Portugal: A discrete choice experiment alongside a trial (USFarmácia®)

Patient Preferences for Pharmacy Services: A Systematic Review of Studies Based on Discrete Choice Experiments

“Prescribing for the whole person”: A qualitative study exploring prescribing pharmacist views on type 2 diabetes management in New Zealand

Contact Info

Product

Resources

About